ROCKVILLE, Md., Oct. 28,
2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a
US-based, global, biotech company, exclusively focused on the
development of highly differentiated immunotherapies for the
treatment of cancer, today announced that management will
participate in one-on-one and small group meetings with investors
at the Truist Securities BioPharma Symposium on November 7, 2024.
Event Details
|
Meeting Date
|
Thursday, November 7,
2024
|
|
Meetings
|
One-on-one and small
group meetings: November 7, 2024
|
|
Management
Participants
|
Sean Fu, PhD, MBA,
Interim Chief Executive Officer (CEO)
Joe Skelton, Chief
Financial Officer (CFO)
Phillip Dennis, MD,
PhD, Chief Medical Officer (CMO)
Tyler Ehler, Senior
Director, Investor Relations
|
For more information, please contact your Truist Securities
representative.
About I-Mab
I-Mab (NASDAQ: IMAB) is a US-based, global biotech company
exclusively focused on the development of highly differentiated
immunotherapies for the treatment of cancer. I-Mab has established
operations in Rockville, Maryland,
and Short Hills, New Jersey. For more information, please
visit https://www.i-mabbiopharma.com and follow us
on LinkedIn and X.
For more information, please contact:
Tyler Ehler
Senior Director, Investor Relations
IR@imabbio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/i-mab-to-participate-at-the-truist-securities-biopharma-symposium-302287758.html
SOURCE I-Mab Biopharma